Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Cancer
Published in: Journal of Gastrointestinal Cancer 1/2020

01-03-2020 | Gastric Cancer | Original Research

Evaluation of the Methylation of MIR129-2 Gene in Gastric Cancer

Authors: Nazila Alizadeh, Milad Asadi, Dariush Shanehbandi, Venus Zafari, Navid Shomali, Touraj Asvadi, Bita Sepehri

Published in: Journal of Gastrointestinal Cancer | Issue 1/2020

Login to get access

Abstract

Background

Genetic and epigenetic changes have strong role in the development of gastric cancer. The mutation of the MIR129-2 gene is one of the major causes in many cancers, especially gastric cancer. The aim of this study was to investigate the methylation changes of the MIR129-2 gene in tumor and normal tissue of patients with gastric cancer.

Method

In this study, 50 gastric cancer patients with Iranian Azari ethnic origin without any familial relations were included. Genomic DNAs was extracted from the tumoral and normal tissues. Then the promotor regions of the MIR129-2 gene were analyzed by methylation-specific PCR (MSP) to evaluate the presence or absence of methylated CpG sites.

Results

There was a statistically significant difference in methylation level of MIR129-2 gene between tumoral and normal tissues. It was observed that 84 out of 100 CpG cites were methylated in tumoral tissues in compression to 13 out of 100 CpG cites in normal tissues.

Conclusion

MIR129-2 gene was hypermethylated in tumoral tissues, suggesting that methylation is involved in the development of gastric cancer.
Literature
1.
Sim, F. and M. McKee, Issues in public health. 2011: McGraw-Hill Education (UK).
2.
Shomali N, Mansoori B, Mohammadi A, Shirafkan N, Ghasabi M, Baradaran B. MiR-146a functions as a small silent player in gastric cancer. Biomed Pharmacother. 2017;96:238–45.CrossRef
3.
Ruddon RW. Cancer biology: Oxford University Press; 2007.
4.
Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clinical endoscopy. 2014;47(6):478.CrossRef
5.
Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. 2017;355(6331):1330–4.CrossRef
6.
Devi, L.I., L. Ralte, and M.A. Ali, Serum biochemical profile of gastric cancer patients.
7.
Ghavifekr Fakhr M, Rezaie Kahkhaie K, Shanehbandi D, Farshdousti Hagh M, Zarredar H, Safarzadeh E, et al. Scrophularia atropatana extract reverses tp53 gene promoter hypermethylation and decreases survivin antiapoptotic gene expression in breast cancer cells. Asian Pac J Cancer Prev. 2018;19(9):2599–605.PubMed
8.
Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–53.CrossRef
9.
Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32.CrossRef
10.
Asadi M, Shanehbandi D, Mohammadpour H, Hashemzadeh S, Sepehri B. Expression level of miR-34a in tumor tissue from patients with esophageal squamous cell carcinoma. J Gastrointest Cancer. 2018.
11.
Mayank, Jaitak V. Drug target strategies in breast cancer treatment: recent developments. Anti Cancer Agents Med Chem. 2014;14(10):1414–27.CrossRef
12.
Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;27(9):1212–22.CrossRef
13.
Shirafkan N, Mansoori B, Mohammadi A, Shomali N, Ghasbi M, Baradaran B. MicroRNAs as novel biomarkers for colorectal cancer: new outlooks. Biomed Pharmacother. 2018;97:1319–30.CrossRef
14.
Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki JM, Cui X, et al. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg. 2014;149(2):125–9.CrossRef
15.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999–3004.CrossRef
16.
Farazi TA, et al. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;774:1–20.CrossRef
17.
Shrestha S, Hsu SD, Huang WY, Huang HY, Chen WL, Weng SL, et al. A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 2014;3(4):878–88.CrossRef
18.
Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, et al. The microRNAs of Caenorhabditis elegans. Genes Dev. 2003;17(8):991–1008.CrossRef
19.
Shen R, Pan S, Qi S, Lin X, Cheng S. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun. 2010;394(4):1047–52.CrossRef
20.
Lee YY, Derakhshan MH. Environmental and lifestyle risk factors of gastric cancer. Arch Iran Med. 2013;16(6):358–65.
21.
Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH, et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer. 2011;129(11):2600–10.CrossRef
22.
Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 2009;34(2):537–42.PubMed
23.
Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009;125(11):2737–43.CrossRef
24.
Liu Y, Hei Y, Shu Q, Dong J, Gao Y, Fu H, et al. VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One. 2012;7(4):e35800.CrossRef
25.
Chen X, Zhang L, Zhang T, Hao M, Zhang X, Zhang J, et al. Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int. 2013;33(3):476–86.CrossRef
26.
Kang M, et al. miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. Int J Mol Med. 2013;32(1):51–8.CrossRef
Metadata
Title
Evaluation of the Methylation of MIR129-2 Gene in Gastric Cancer
Authors
Nazila Alizadeh
Milad Asadi
Dariush Shanehbandi
Venus Zafari
Navid Shomali
Touraj Asvadi
Bita Sepehri
Publication date
01-03-2020
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 1/2020
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00239-4

Other articles of this Issue 1/2020

Journal of Gastrointestinal Cancer 1/2020 Go to the issue

Case Report

An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report

Original Research

Whole Exome Sequencing Reveals a Novel Damaging Mutation in Human Fibroblast Activation Protein in a Family with Esophageal Squamous Cell Carcinoma

Case Report

Resection of Adrenal Metastasis Invading Left Renal Vein Following Living Donor Liver Transplantation for Hepatocellular Carcinoma

Original Research

The Unusual Suspects of the Pancreas—Understanding Pancreatic Acinar Cell Carcinomas and Adenomas

Original Research

Trends in Mortality Rates for Gastrointestinal Cancers in Fars Province, Iran (2005–2015)

Original Research

Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits